Medical Information (MI), Pharmacovigilance (PV) and Regulatory Affairs (RA) each play distinct but deeply interconnected roles in ensuring that therapeutics are safe, accurately labeled and compliantly communicated to healthcare professionals and patients. Yet in practice, the boundaries between these functions are rarely clean; a safety signal surfaced through an MI inquiry can trigger a PV investigation, which in turn may prompt a label update, a Risk Management Plan revision and coordinated external communications. When these handoffs work well, they are nearly invisible. When they break down, the consequences can be significant. This webinar brings together experienced cross-functional practitioners to examine how MI, PV and RA collaborate across the full product lifecycle, from the moment an inquiry arrives to the resolution of a safety crisis. Panelists will walk through the critical touchpoints that define effective collaboration: how potential adverse events are identified and escalated from MI to PV; how RA maintains labeling consistency in response to evolving safety data; and how all three functions align on response development for complex or sensitive inquiries, including off-label use scenarios. The session will also address the realities of cross-functional work, including common pitfalls in communication and decision-making, and what organizations can do to avoid them. Particular attention will be given to crisis and escalation management, exploring how teams can build the structures and relationships needed to respond swiftly and cohesively when urgent safety situations arise. Looking ahead, the panel will explore how the roles of MI, PV and RA are evolving in an increasingly